Study Name: OSTEOARTHRITIS KNEE
Therapy Area: Osteoarthritis
Gender and Age: Males & Females (not of childbearing potential) aged 30-79
MAC Clinical Research is currently conducting a clinical trial to investigate a potential new treatment for osteoarthritis of the knee. Osteoarthritis (OA) is a disease where the surfaces of joints become damaged, causing stiffness and pain. OA most commonly affects the knees, hips, neck, back, toes and fingers. Treatments are available for OA, but they don’t always work well and can have troublesome side effects.
The purpose of this trial is to test a new potential treatment for osteoarthritis in participants with osteoarthritis of the knee, and to see how safe and well tolerated it is. During the trial, eligible participants will receive the trial medication or placebo once by a single injection into a vein. For every 7 participants, 5 will receive the trial medication and 2 will receive placebo. There will be 10 outpatient visits and 1 inpatient stay of 4 consecutive nights to our Manchester clinic over the 5-month trial period.
Reimbursement: Up to £2050
Key Inclusion Criteria
Male or female (not of childbearing potential) aged 30 to 79
Diagnosis of osteoarthritis of the knee
Have a BMI between 18 and <40
Key Exclusion Criteria
Diagnosis of any other arthritis, pain condition or autoimmune disease (e.g. rheumatoid arthritis, other inflammatory arthritis, gout, fibromyalgia, osteonecrosis).
Unable to refrain from taking pain relief medications for the duration of the trial (except for paracetamol).
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information:
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.